Ethylene glycol-O,O'-bis(2-aminoethyl)-N,N,N',N'-tetraacetic acid, 97.0%, 25g

5-Bromo-4-chloro-3-indolyl acetate, 95.0%, 250mg

METHYL 7-BROMO-5-FLUOROBENZOFURAN-2-CARBOXYLATE, 95.0%, 100mg

N-(PYRIDIN-2-YL)FORMAMIDE, 95.0%, 1g

9,9-Difluoro-3-oxa-7-azabicyclo[3.3.1]nonane, 97%, 1g

2,6-Diethylaniline>98.0%(GC)(T)100mL

2,4-Dichlorophenylacetone>98.0%(GC)25g

2-Amino-5-[2-(trifluoromethyl)phenyl]-1,3,4-thiadiazole, 98.0%, 100mg

1-Benzhydrylazetidine, 95.0%, 100g

E-Plan phase EPLPHi 20x/0.40 infinity corrected IOS objective. Working distance 2.61 mm

5-(2-Bromo-4-fluorophenyl)-1,3,4-oxadiazol-2-amine, 95%, 1g

Ethyl 1H-pyrrolo[3,2-b]pyridine-2-carboxylate, 95.0%, 25g

Ethyl 2,4-dimethoxybenzoate, 98.0%, 25g